GENERIC MANUFACTURERS

State and Federal Price Reporting and Financial Disclosures


What the growing number of mandatory pharmaceutical price and financial disclosure laws and prescription drug costs mean to you.

Mandatory pharmaceutical price and/or financial disclosure laws are intended to increase price transparency to address concerns about prescription drug costs. Ultimately, federal and state regulators view these requirements as an initial step in controlling the cost of pharmaceuticals.

For you, it means staying on top of many diverse rule sets among the states. No two are alike and there is a wide variety of mandated notification periods. States have already started to be aggressive in levying fines for non-compliance.

As of early 2020, 19 states have specific regulations that require varying degrees of price reporting or financial disclosure requirements. There are also 19 states considering additional transparency legislation. No two states are alike, and there is a wide variety of mandated notification rule sets. States have already started to be aggressive in levying fines for non-compliance, increasing the importance of staying on top of diverse state requirements. Learn more by reading our latest white paper.

Download a summary of our services for generic pharmaceutical manufacturers.

Services for Generic Manufacturers

Our role: communicate, model, monitor, track, and keep you compliant.

Services include:

  • Track state, territorial and federal price reporting requirements
  • Integrate with client product pricing team
  • Provide required impact analytics related to contemplated pricing and price adjustments
  • Prepare and submit required notifications to state, territorial and federal regulatory authorities